인메드 파마슈티컬스INM 주가

[SCHEDULE 13G] SCHEDULE 13G

InMed Pharmaceuticals Inc. (INM) M&A Call Prepared Remarks Transcript

InMed Pharmaceuticals Inc. (INM) M&A Call May 19, 2026 8:30 AM EDTCompany ParticipantsColin Clancy - VP of Investor Relations & Corporate...

[4] 내부자 거래 — PRIMARY DOCUMENT

[3] 3 — PRIMARY DOCUMENT

12 Health Care Stocks Moving In Tuesday's Intraday Session

Gold Falls 1%; Amer Sports Earnings Top Views

US stocks down, Nasdaq drops 200 points. Dow -0.35% at 49,512.48, Nasdaq -0.93% at 25,849.08, S&P 500 -0.56% at 7,361.93. Health care up 1.2%, materials down 2.1%. Amer Sports beats Q1 earnings, stock up 198%. Oil up 0.1%, gold down 1.3%, silver down 3.5%, copper down 1.9%. European and Asian markets mixed.

Dow Falls Over 100 Points; Home Depot Posts Upbeat Earnings

US stocks fall, Dow Jones down 0.34% & NASDAQ down 0.41% in morning trading. Home Depot reports upbeat earnings, while materials stocks drop 1.8%.

Penny Stock InMed Pharmaceuticals Merger Deal Targets Migraine Pipeline

InMed agrees to merge with Mentari Therapeutics to advance migraine drug candidates backed by $290 million in financing.

UPDATE: InMed Pharmaceuticals To Merge With Mentari Therapeutics In All-Stock Deal Backed By $290M Private Placement, Combined Company Valued At $421.4M; InMed Shareholders to Own 1.51% Stake

About the Proposed TransactionUnder the terms of the merger agreement, as of the closing of the proposed merger, the pre-merger InMed shareholders are expected to own approximately 1.51% of the combined company, which is

InMed Pharmaceuticals To Merge With Mentari Therapeutics

Upon consummation of the transaction contemplated by the Agreement, the combined entity will operate as Mentari Therapeutics and trade on the Nasdaq Capital Market under a new ticker symbol. Mentari's parallel lead